ADHD: ArkBio Announces the Completion of Phase III Clinical Study for AK0901
Shanghai Ark Biopharmaceutical Co., Ltd. („ArkBio“) today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity disorder (ADHD). This milestone represents a substantial step forward for ArkBio in the research and development of drugs for pediatric psychiatric disorders, potentially offering new treatment options and improved therapeutic outcomes for children with ADHD in China. ADHD is a chronic neurodevelopmental disorder characterized by age-inappropriate attention deficits and/or hyperactivity-impulsivity, often persisting into adulthood. Globally, approximately 7.2% of children are affected, with 60%–80% continuing to exhibit symptoms during adolescence and 50.9% into adulthood. About 65% of patients present with one or more comorbidities. ADHD impairs learning and causes multidimensional, lifelong functional challenges. In China, the prevalence of ADHD among children and adolescents is 6.4%, affecting over 23 million individuals. However, current…
